Patrys Reshapes Board, Raises $308K, Eyes $1.77M Boost for Clinical Push

• Completed $308,362 capital raise with new share placement
• Board and management restructuring including new Chair and director appointments
• Active pursuit of partnering and licensing for deoxymab assets, especially PAT-DX3
• Cash balance of $742,000 plus expected $790,000 R&D tax refund in H2 2025